Clinical Trial

ICP-332 in Subjects With Non-segmental Vitiligo

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This a phase II/III randomized, double-blind, placebo-controlled, parallel group, adaptive design, multi-center study to evaluate the efficacy and safety of ICP-332 in subjects with non-segmental vitiligo。The study consisted an phase 2 part and an phase 3 part.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-23.
Trial Details
NCT Number NCT07047612
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Non Segmental Vitiligo
Enrollment 603 participants
Start Date 2025-05-09
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-07